{"Title": "Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors", "Year": 2017, "Source": "New Engl. J. Med.", "Volume": "376", "Issue": 2, "Art.No": null, "PageStart": 125, "PageEnd": 135, "CitedBy": 878, "DOI": "10.1056/NEJMoa1607427", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85009286837&origin=inward", "Abstract": "Copyright \u00a9 2017 Massachusetts Medical Society.BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)'Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progressionfree survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. RESULTS At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate group and 26 in the control group (P = 0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the 177Lu-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. CONCLUSIONS Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239; EudraCT number 2011-005049-11.).", "AuthorKeywords": null, "IndexKeywords": ["Aged", "Antineoplastic Agents", "Delayed-Action Preparations", "Disease-Free Survival", "Drug Administration Schedule", "Female", "Gastrointestinal Neoplasms", "Humans", "Infusions, Intravenous", "Kaplan-Meier Estimate", "Male", "Middle Aged", "Nausea", "Neuroendocrine Tumors", "Octreotide", "Organometallic Compounds"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85009286837", "SubjectAreas": [["Medicine (all)", "MEDI", "2700"]], "AuthorData": {"12763097300": {"Name": "Strosberg J.", "AuthorID": "12763097300", "AffiliationID": "60004803", "AffiliationName": "Moffitt Cancer Center"}, "10339400400": {"Name": "El-Haddad G.", "AuthorID": "10339400400", "AffiliationID": "60004803", "AffiliationName": "Moffitt Cancer Center"}, "7004294756": {"Name": "Wolin E.", "AuthorID": "7004294756", "AffiliationID": "60027155, 60015941", "AffiliationName": "Markey Cancer Center, University of Kentucky"}, "8870070900": {"Name": "Hendifar A.", "AuthorID": "8870070900", "AffiliationID": "60016173", "AffiliationName": "Cedars Sinai Medical Center"}, "6505898489": {"Name": "Mittra E.", "AuthorID": "6505898489", "AffiliationID": "60032838", "AffiliationName": "Stanford University School of Medicine"}, "12800050500": {"Name": "Kunz P.L.", "AuthorID": "12800050500", "AffiliationID": "60032838", "AffiliationName": "Stanford University School of Medicine"}, "57201990575": {"Name": "Yao J.", "AuthorID": "57201990575", "AffiliationID": "60015023", "AffiliationName": "University of Texas M.D. Anderson Cancer Center"}, "25930766300": {"Name": "Chasen B.", "AuthorID": "25930766300", "AffiliationID": "60015023", "AffiliationName": "University of Texas M.D. Anderson Cancer Center"}, "6604044534": {"Name": "Delpassand E.", "AuthorID": "6604044534", "AffiliationID": "101398010", "AffiliationName": "Excel Diagnostics Imaging Clinic"}, "6701489028": {"Name": "Kulke M.H.", "AuthorID": "6701489028", "AffiliationID": "60014334", "AffiliationName": "Dana-Farber Cancer Institute"}, "8532575900": {"Name": "Jacene H.", "AuthorID": "8532575900", "AffiliationID": "60014334", "AffiliationName": "Dana-Farber Cancer Institute"}, "57210199612": {"Name": "Bushnell D.", "AuthorID": "57210199612", "AffiliationID": "60024324", "AffiliationName": "University of Iowa"}, "7101937690": {"Name": "O'Dorisio T.M.", "AuthorID": "7101937690", "AffiliationID": "60024324", "AffiliationName": "University of Iowa"}, "55579753600": {"Name": "Baum R.P.", "AuthorID": "55579753600", "AffiliationID": "101441630", "AffiliationName": "Zentralklinik"}, "47161378700": {"Name": "Kulkarni H.R.", "AuthorID": "47161378700", "AffiliationID": "101441630", "AffiliationName": "Zentralklinik"}, "7005087885": {"Name": "Pavel M.", "AuthorID": "7005087885", "AffiliationID": "60026245", "AffiliationName": "Charite-Universitatsmedizin"}, "55908628800": {"Name": "Caplin M.", "AuthorID": "55908628800", "AffiliationID": "101010478", "AffiliationName": "Royal Free Hospital"}, "24484968400": {"Name": "Srirajaskanthan R.", "AuthorID": "24484968400", "AffiliationID": "60029685", "AffiliationName": "King's College Hospital NHS Foundation Trust"}, "35941546100": {"Name": "Reed N.", "AuthorID": "35941546100", "AffiliationID": "60000265", "AffiliationName": "Beatson Oncology Centre"}, "7003757847": {"Name": "Lebtahi R.", "AuthorID": "7003757847", "AffiliationID": "60005915", "AffiliationName": "Hopital Beaujon"}, "7005561095": {"Name": "Ruszniewski P.", "AuthorID": "7005561095", "AffiliationID": "60005915", "AffiliationName": "Hopital Beaujon"}, "57192941428": {"Name": "Thevenet T.", "AuthorID": "57192941428", "AffiliationID": "101797908", "AffiliationName": "Advanced Accelerator Applications"}, "6602621393": {"Name": "Hobday T.", "AuthorID": "6602621393", "AffiliationID": "60026829", "AffiliationName": "Mayo Clinic College of Medicine"}, "57212668756": {"Name": "Van Cutsem E.", "AuthorID": "57212668756", "AffiliationID": "60031069, 60025063", "AffiliationName": "University Hospitals and KU Leuven"}, "35261661800": {"Name": "Benson A.", "AuthorID": "35261661800", "AffiliationID": "60013227", "AffiliationName": "Robert H. Lurie Comprehensive Cancer Center"}, "57217509062": {"Name": "Mora J.", "AuthorID": "57217509062", "AffiliationID": "60011805", "AffiliationName": "Hospital Universitari de Bellvitge"}, "16554800300": {"Name": "Grande E.", "AuthorID": "16554800300", "AffiliationID": "60021609", "AffiliationName": "Hospital Universitario Ramon y Cajal"}, "7102054245": {"Name": "Berlin J.", "AuthorID": "7102054245", "AffiliationID": "60030769", "AffiliationName": "Vanderbilt University Medical Center"}, "7005385154": {"Name": "Seregni E.", "AuthorID": "7005385154", "AffiliationID": "60006583", "AffiliationName": "Fondazione Istituto di Ricovero, Cura A Carattere Scientifico Istituto Nazionale Dei Tumori"}, "7102283805": {"Name": "\u00d6berg K.", "AuthorID": "7102283805", "AffiliationID": "60015216, 60003858", "AffiliationName": "University Hospital, Uppsala University"}, "7101602141": {"Name": "Sierra M.L.", "AuthorID": "7101602141", "AffiliationID": "118990947", "AffiliationName": "Advanced Accelerator Applications USA"}, "57192940340": {"Name": "Santoro P.", "AuthorID": "57192940340", "AffiliationID": "118990947", "AffiliationName": "Advanced Accelerator Applications USA"}, "6701859181": {"Name": "Erion J.L.", "AuthorID": "6701859181", "AffiliationID": "118990947", "AffiliationName": "Advanced Accelerator Applications USA"}, "7006184062": {"Name": "Kwekkeboom D.", "AuthorID": "7006184062", "AffiliationID": "60032114", "AffiliationName": "Erasmus Medical Center"}, "25223130400": {"Name": "Krenning E.", "AuthorID": "25223130400", "AffiliationID": "60032114", "AffiliationName": "Erasmus Medical Center"}}}